Pharmaceutical QRM SOP: ICH Q9 Operations

Standard Operating Procedure: Quality Risk Management (QRM)

This Standard Operating Procedure (SOP) outlines the systematic framework for Quality Risk Management (QRM) within pharmaceutical operations. Aligned with ICH Q9 guidelines, this procedure ensures that risks to product quality and patient safety are identified, assessed, controlled, communicated, and reviewed throughout the product lifecycle. The objective is to facilitate proactive, science-based decision-making to mitigate deviations, contamination, and non-compliance.

1. Risk Assessment Phase

• Define the Problem: Clearly articulate the specific risk question, including the potential for harm to the patient or process integrity.
• Assemble the Team: Appoint a cross-functional team (QA, Production, Engineering, Regulatory) to ensure diverse subject matter expertise.
• Information Gathering: Collect historical data, batch records, deviation logs, and current regulatory requirements pertinent to the identified risk.
• Select Methodology: Choose an appropriate risk assessment tool (e.g., FMEA, FTA, HACCP, or PHA) based on the complexity of the process.

2. Risk Control and Mitigation

• Risk Evaluation: Determine the probability of occurrence, severity of the impact, and detectability of the risk using a predefined risk matrix.
• Establish Acceptability: Compare the calculated risk score against the company’s "Risk Acceptance Criteria."
• Implement Controls: Design and execute strategies to reduce risk (e.g., equipment upgrades, revised SOPs, enhanced training, or automated monitoring).
• Residual Risk Review: Re-evaluate the process after control implementation to ensure that residual risk is within acceptable thresholds.

3. Communication and Review

• Formal Documentation: Document all findings, decisions, and risk-reduction measures in the Quality Risk Register.
• Communication Strategy: Inform stakeholders and department heads of the identified risks and the steps taken to minimize them.
• Ongoing Monitoring: Schedule periodic reviews of the risk register to account for process changes, technological advancements, or new regulatory guidance.
• CAPA Integration: Ensure that any high-level risks identified are linked to the Corrective and Preventive Action (CAPA) system for tracking and closure.

Pro Tips & Pitfalls

Pro Tips

• Use Visuals: Incorporate Risk Scoring Matrices (e.g., 5x5 matrices) to make the impact levels intuitive for the team.
• Evidence-Based: Always anchor your risk scoring in empirical data rather than "gut feeling." Reference batch records or previous audit findings.
• Living Document: Treat the risk register as a living document. Update it whenever a major change control is initiated.

Pitfalls

• Subjectivity Bias: Over-reliance on the subjective opinion of a single manager; always use a multi-disciplinary panel to neutralize bias.
• Ignoring Detectability: Focus too much on "Probability" and "Severity" while forgetting that the inability to detect a defect is often the greatest risk factor.
• "Set and Forget": Performing a risk assessment during launch and never reviewing it again is a major regulatory compliance failure.

Template Document: Pharmaceutical QRM SOP: ICH Q9 Operations

This Standard Operating Procedure establishes the systematic process for performing Quality Risk Management (QRM) activities in alignment with ICH Q9 principles to ensure product quality and patient safety. It is intended for use by quality assurance personnel, manufacturing leads, and regulatory compliance teams involved in risk-based decision-making.

• Document owner: [Department Name]
• Effective date: [Date]
• Version: [Version number]
• Applies to: [Process or Facility Name]

Roles and responsibilities

Steps

1. Define the scope and objective of the risk assessment, including the specific [Process or System Name] being evaluated.
2. Assemble the cross-functional team and assign the [Role Name] to document all identified hazards.
3. Identify potential failure modes using a structured tool such as FMEA or PHA for the [Process Step].
4. Assign a severity, occurrence, and detectability score to each hazard based on the [Risk Scoring Matrix].
5. Calculate the Risk Priority Number by multiplying the three scores to determine the [Risk Level].
6. Compare the calculated risk against the [Acceptability Threshold] to determine if further action is required.
7. Develop a mitigation plan for all risks exceeding the threshold, specifying the [Action Item] and the responsible person.
8. Verify that the proposed risk control measures do not introduce new hazards to the [Manufacturing Environment].
9. Document the residual risk after mitigation and obtain formal sign-off from the [Quality Manager Name].
10. Schedule a periodic review of the risk assessment to occur no later than [Date] to ensure continued effectiveness.
11. Communicate the final risk assessment findings to the [Department Head] for integration into the quality management system.
12. Archive the completed risk assessment report in the [Document Management System] for future audit readiness.

Record of completion

• Prepared by: [Full name]
• Reviewed by: [Full name]
• Date completed: [Date]
• Signature: ______________________
• Date signed: [Date]

Frequently Asked Questions (FAQ)

Q1: How often should we review our Quality Risk Management files? A: Risk assessments should be reviewed periodically (typically annually) or triggered by specific events such as major equipment changes, significant deviations, or changes in regulatory standards.

Q2: What is the most common tool used in Pharma QRM? A: Failure Mode and Effects Analysis (FMEA) is the industry standard because it provides a structured way to score risks based on Severity, Occurrence, and Detectability.

Q3: Does QRM replace traditional quality control? A: No. QRM is a proactive tool meant to complement traditional Quality Control and Quality Assurance. It helps prioritize resources, but it does not eliminate the requirement for routine testing and inspection.